BioSyngen

BioSyngen is a leading biotechnology research company dedicated to addressing unmet needs through innovative cell therapies. BioSyngen focuses on developing groundbreaking treatments for solid tumors and lymphoproliferative diseases. With first-in-class products already in Phase I/II clinical trials for conditions such as nasopharyngeal cancer, lymphoproliferative disease, and lung cancer, BioSyngen is committed to enriching its pipeline and advancing regulatory submissions.

Operating from its global headquarters at 5 Tai Seng Avenue, #08-51, Hougang, North East Community Development Council 536671, SG, BioSyngen drives its international strategy with a clinical center in Guangzhou, China. The company leverages a robust public-private biopharma ecosystem to further its mission of providing cancer patients with improved survival chances. BioSyngen's pipeline is continuously expanding, covering major indications and progressing toward regulatory registration.

BioSyngen is actively seeking collaborations to foster breakthroughs in translational R&D and clinical development. With strategically positioned GMP cell therapy manufacturing facilities in both Singapore and Guangzhou, BioSyngen ensures comprehensive global coverage. Furthermore, the establishment of a Translational Medicine Centre, a public-private partnership connecting key stakeholders, accelerates drug development from bench-to-bedside. The BioSyngen team looks forward to providing more information about their capabilities soon.

We invite the BioSyngen team to create a customized and exclusive company showcase and product listing on our platform.